TGTX, 3/1-3/8, -2% loss

On 2/28/2024, TG Therapeutics (TGTX) reported a loss of $0.09 per share on revenue of $43.97 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.12 per share on revenue of $40.06 million.